Astec Lifesciences Share Price Jumps 17% to Rs 691 Even as Sensex, Nifty Slide on Crude Oil Surge
Add Preferred News Source
The sharp rise came alongside a company clarification on higher trading volumes, while its June-quarter results showed a sharp reduction in operating losses despite weaker income.
Astec Lifesciences shares bucked a weak market on Wednesday, September 9, with the stock rising as much as 17% on the NSE. The stock opened at Rs 691, against Tuesday's close of Rs 662.80, and extended gains during the session even as the broader market came under pressure.
The sharp move came on a day when rising crude oil prices and renewed tensions in West Asia weighed on Indian equities. The Sensex fell 500.25 points to 75,060.61 in early trade, while the Nifty50 declined 129.40 points to 23,506.10. Brent crude was trading close to the $100-a-barrel mark as concerns over oil supplies from the region increased.
Astec Lifesciences' rally also came amid a sharp rise in trading volumes, prompting the company to issue a clarification to the exchanges on September 9.
Astec Lifesciences clarifies trading volume
In its exchange filing, the company said it was conscious of its responsibility as a listed company to disclose information that could have an impact on its share price. It said it had been promptly disseminating events and information that require disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The company said it had complied with the disclosure requirements under the listing regulations and SEBI norms. It also confirmed that there were no developments that had taken place which required mandatory disclosure under the applicable regulations.
The clarification came as the stock witnessed a significant increase in trading volume. With no new price-sensitive development disclosed by the company, the sharp rise in the stock remains notable against the broader market weakness.
Astec Lifesciences Q1 results show narrower loss
Astec Lifesciences reported a mixed performance for the June quarter, with total income declining but operating losses reducing sharply.
Consolidated total income stood at Rs 84.3 crore in Q1 FY27, compared with Rs 91.6 crore in the year-ago quarter. This marked a decline of Rs 7.3 crore in total income during the period.
At the operating level, however, the company reported a significant improvement. Consolidated EBITDA stood at Rs 0.1 crore in Q1 FY27, compared with a negative EBITDA of Rs 10.5 crore in Q1 FY26. The company therefore moved from an operating loss to marginally positive EBITDA during the quarter.
The improvement at the operating level also helped reduce the company's loss after tax. Astec Lifesciences reported a consolidated net loss of Rs 18.7 crore in Q1 FY27, compared with a loss of Rs 33 crore in the corresponding quarter last year.
While the company continued to remain loss-making, the quarterly numbers showed a substantial reduction in both operating losses and net loss despite the decline in total income. The stock's sharp rise on Wednesday, meanwhile, came without any fresh mandatory disclosure from the company, leaving trading activity and the latest financial performance as the key developments in focus.
Also Read - Reliance, IndiGo, Asian Paints Under Pressure as Crude Hits 15-Week High, Nears $100 Amid Iran-US Tension
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Rochelle Britto has spent 8+ years decoding India's markets, businesses, and consumer economy, reporting for ET Prime and Times Internet along the way, covering the stories behind the numbers.
A Mumbai native and perpetual planner of the next holiday, she stays far, far away from the eternal question, “Where are we going next?” When she's not chasing headlines, she's chasing new cultures, open roads, and a bit of quiet in nature.
Right Tools, Rich Insights
